Feasibility of Radioimmunotherapy of Experimental Pneumococcal Infection

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 5, 2004, Pages 1624-1629

  Dadachova, E ^a   Burns, T ^a   Bryan, R A ^a   Apostolidis, C ^b   Brechbiel, M W ^c   Nosanchuk, J D ^a   Casadevall, A ^a   Pirofski, L ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b JOINT RESEARCH CENTRE   (Italy)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH 213; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY D11; PNEUMOCOCCUS POLYSACCHARIDE; UNCLASSIFIED DRUG;

ALPHA RADIATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIGEN BINDING; ARTICLE; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BLOOD TOXICITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG CONJUGATION; DRUG EFFECT; DRUG SCREENING; IN VITRO STUDY; ISOTOPE LABELING; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SEROTYPE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; THROMBOCYTE COUNT;

ANIMALS; ANTIBODIES, MONOCLONAL; BISMUTH; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MICE; MICE, INBRED C57BL; PLATELET COUNT; PNEUMOCOCCAL INFECTIONS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; STREPTOCOCCUS PNEUMONIAE;

EID: 2142812932     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.5.1624-1629.2004     Document Type: Article

References (29)

1. Adams, G. P., C. C. Shaller, L. L. Chappell, C. Wu, E. M. Horak, H. H. Simmons, S. Litwin, J. D. Marks, L. M. Weiner, and M. W. Brechbiel. 2000. Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules. Nucl. Med. Biol. 27:339-346.
2. Andersson, H., J. Elgqvist, G. Horvath, R. Hultborn, L. Jacobsson, H. Jensen, B. Karlsson, S. Lindegren, and S. Palm. 2003. Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model. Clin. Cancer Res. 9:3914S-3921S.
3. Appelbaum, P. C. 2002. Resistance among Streptococcus pneumoniae: implications for drug selection. Clin. Infect. 34:1613-1620.
4. Behr, T. M., M. Behe, M. G. Stabin, E. Wehrmann, C. Apostolidis, R. Molinet, F. Strutz, A. Fayyazi, E. Wieland, S. Gratz, L. Koch, D. M. Goldenberg, and W. Becker. 1999. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model. Cancer Res. 59:2635-2643.
5. Bishayee, A., D. V. Rao, and R. W. Howell. 1999. Evidence for pronounced bystander effects caused by nonuniform distributions of radioactivity using a novel three-dimensional tissue culture model. Radiat. Res. 152:88-97.
6. Boll, R. A., S. Mirzadeh, and S. J. Kennel. 1997. Optimization of radiolabeling of immunoproteins with 213Bi. Radiochim. Acta 79:145-149.
7. Buchwald, U. K., and L. Pirofski. 2003. Immune therapy for infectious diseases at the dawn of the 21st century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers. Curr. Pharm. Des. 9:945-968.
8. Burns, T., Z. Zhong, M. Steinitz, and L. Pirofski. 2003. Modulation of polymorphonuclear cell interleukin-8 secretion by human monoclonal antibodies to type 8 pneumococcal capsular polysaccharide. Infect. Immun. 71:6775-6783.
9. Casadevall, A., and M. D. Scharff. 1994. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob. Agents Chemother. 38:1695-1702.
10. Casarett, A. P. 1968. Radiation biology. Prentice-Hall, Englewood Cliffs, N.J.
11. Chang, Q., Z. Zhong, A. Lees, M. Pekna, and L. Pirofski. 2002. Structure-function relationships for human antibodies to pneumococcal capsular polysaccharide from transgenic mice with human immunoglobulin loci. Infect. Immun. 70:4977-4986.
12. Chappell, L. L., E. Dadachova, D. E. Milenic, K. Garmestani, and M. W. Brechbiel. 2000. Synthesis and characterization of a novel bifunctional chelating agent for lead(II). Conjugation to a monoclonal antibody, radiolabeling with Lead-203 and serum stability determination. Nucl. Med. Biol. 27: 93-100.
13. Dadachova, E., A. Nakouzi, R. Bryan, and A. Casadevall. 2003. Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc. Natl. Acad. Sci. USA 100:10942-10947.
14. Dadachova, E., R. W. Howell, R. A. Bryan, A. Frenkel, J. D. Nosanchuk, and A. Casadevall. 2004. Susceptibility of human pathogens Cryptococcus neoformans and Histoplasma capsulatum to gamma radiation versus radioimmunotherapy with alpha- and beta-emitting radioisotopes. J. Nucl. Med. 45: 313-320.
15. Dadachova, E., R. A. Bryan, A. Frenkel, T. Zhang, C. Apostolidis, J. S. Nosanchuk, J. D. Nosanchuk, and A. Casadevall. 2004. Acute hematological and long-term pulmonary toxicity of radioimmunotherapy of Cryptococcus neoformans infection in murine models. Antimicrob. Agents Chemother. 48:1004-1006.
16. Edmonds, C. J., and T. Smith. 1986. The long-term hazards of the treatment of thyroid cancer with radioiodine. Br. J. Radiol. 59:45-51.
17. Goldenberg, D. M. (ed.). 1995. Cancer therapy with radiolabeled antibodies. CRC Press, Inc., Boca Raton, Fla.
18. Kozak, R. W., R. W. Atcher, O. A. Gansow, A. M. Friedman, J. J. Hines, and T. A. Waldmann. 1986. Bismuth-212-labeled anti-Tac monoclonal antibody: alpha particle-emitting radionuclides as modalities for radioimmunotherapy. Proc. Natl. Acad. Sci. USA 83:474-478.
19. McDevitt, M. R., E. Barendswaard, D. Ma, L. Lai, M. J. Curcio, G. Sgouros, A. M. Ballangrud, W. H. Yang, R. D. Finn, V. Pellegrini, M. W. Geerlings, M. Lee, M. W. Brechbiel, N. H. Bander, C. Cordon-Cardo, and D. A. Scheinberg. 2000. An alpha particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. 60:6095-6100.
20. Miale, J. B. 1982. Laboratory medicine hematology, p. 864. The CV Mosby Company, St. Louis, Mo.
21. Mirzadeh, S., M. W. Brechbiel, R. W. Atcher, and O. A. Gansow. 1990. Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl)diethylenetriamine-pentaacetic acid ligands to immunoglobulin. Bioconjug. Chem. 1:59-65.
22. Pippin, C. G., T. A. Parker, T. J. McMurry, and M. W. Brechbiel. 1992. Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. Bioconjug. Chem. 3:342-345.
23. Pirofski, L-A., and A. Casadevall. 1998. Use of licensed vaccines for active immunization of the immunocompromised host. Clin. Microbiol. Rev. 11:1-26.
24. Ryan, K. J. (ed.). 1994. Sherris medical microbiology. An introduction to infectious diseases. Appleton & Lange, Norwalk, Conn.
25. Senekowitsch-Schmidtke, R., C. Schuhmacher, K. F. Becker, T. K. Nikula, C. Seidl, I. Becker, M. Miederer, C. Apostolidis, C. Adam, R. Huber, E. Kremmer, K. Fischer, and M. Schwaiger. 2001. Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer. Cancer Res. 61:2804-2808.
26. Sgouros, G., A. M. Ballangrud, J. G. Jurcic, M. R. McDevitt, J. L. Humm, Y. E. Erdi, B. M. Mehta, R. D. Finn, S. M. Larson, and D. A. Scheinberg. 1999. Pharmacokinetics and dosimetry of an alpha particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J. Nucl. Med. 40:1935-1946.
27. Wentworth, P., Jr., J. E. McDunn, A. D. Wentworth, C. Takeuchi, J. Nieva, T. Jones, C. Bautista, J. M. Ruedi, A. Gutierrez, K. D. Janda, B. M. Babior, A. Eschenmoser, and R. A. Lerner. 2002. Evidence for antibody-catalyzed ozone formation in bacterial killing and inflammation. Science 298:2195-2199.
28. Xue, L. Y., N. J. Butler, G. M. Makrigiorgos, S. J. Adelstein, and A. I. Kassis. 2002. Bystander effect produced by radiolabeled tumor cells in vivo. Proc. Natl. Acad. Sci. USA 99:13765-13770.
29. Zhong, Z., T. Burns, Q. Chang, M. Carroll, and L. Pirofski. 1999. Molecular and functional characteristics of a protective human monoclonal antibody to serotype 8 Streptococcus pneumoniae capsular polysaccharide. Infect. Immun. 67:4119-4127.